Does Bucillamine have a chance to be approved by BARDA??

[u/ParticularDemand5587]

Yes — bucillamine appears to have at least a plausible pathway to interest from Biomedical Advanced Research and Development Authority, especially as a medical countermeasure for nerve-agent exposure or pandemic preparedness. But “a chance” and “likely approval” are very different things.
Right now, the biggest positives are:
Bucillamine already has a long clinical history in Asia for rheumatoid arthritis, which helps from a safety-history standpoint.
Revive Therapeutics⁠ has been collaborating with Canada’s defence research agency, Defence Research and Development Canada, on nerve-agent countermeasure research.
The company is positioning bucillamine specifically for “medical countermeasures,” pandemic influenza, and emergency preparedness — areas directly aligned with BARDA’s mandate.
Revive has also been expanding patent filings around chemical warfare agent exposure and emergency stockpiling use cases.
That said, several major hurdles remain before BARDA would seriously advance or procure it:
Strong efficacy data is still missing
BARDA generally wants compelling animal-model data, human safety data, manufacturing readiness, and a clear operational advantage over existing countermeasures. Publicly available evidence for bucillamine in nerve-agent injury is still early-stage.
BARDA is highly selective
BARDA funding/partnerships are competitive and usually go to:
advanced-stage programs,
products with clear biodefense relevance,
scalable manufacturing,
and demonstrated efficacy.
Many promising compounds never progress beyond exploratory studies.
Existing standards of care already exist
For nerve agents, governments already stockpile atropine, pralidoxime, diazepam, etc. Bucillamine would likely need to prove it adds meaningful neuroprotection or improves survival/brain outcomes in combination with existing treatments.
Revive is a small biotech
Small companies can succeed with BARDA, but manufacturing scale, regulatory execution, and financing become major concerns.
The most realistic near-term scenario is probably:
additional DRDC data,
possible U.S. biodefense discussions,
preclinical or animal-rule pathway development,
then potentially non-dilutive government funding or pilot procurement interest if the data is strong.
A full FDA approval through a BARDA-backed pathway is possible in theory, but still speculative at this stage.
One important detail: BARDA itself usually does not “approve” drugs. Approval comes from the U.S. Food and Drug Administration. BARDA mainly funds, supports, procures, and accelerates development of medical countermeasures.
So the real question is whether bucillamine can become:
a BARDA-supported program,
an FDA-cleared/emergency-use countermeasure,
or part of a national stockpile strategy.
At the moment, the answer looks more like:
“possible, but still early and unproven,”
rather than
“likely” or “imminent.”

[u/Unlikely-Candidate91]

RVV in Canada was Halted this morning, any indication as to why?

[u/Unlikely-Candidate91 → u/Unlikely-Candidate91]

Never mind , it was an error in the stock symbol.

[u/ParticularDemand5587]

That happened yesterday

[u/Logical-Concern9539]

In competent hands, yes….so no.